太平洋医药日报（20250529）：诺华伊普可泮在华获批新适应症

Investment Rating - The industry rating is neutral for the biopharmaceutical sector and other pharmaceutical sectors, while the chemical pharmaceutical sector has no rating [2][9]. Core Insights - The pharmaceutical sector experienced a rise of 2.37% on May 29, 2025, outperforming the CSI 300 index by 1.81 percentage points, ranking second among 31 sub-industries in the Shenwan classification. The best-performing sub-industries included medical research outsourcing (+5.34%), other biological products (+3.79%), and in vitro diagnostics (+2.33%), while offline pharmacies (-1.61%), medical devices (+0.65%), and pharmaceutical distribution (+0.66%) lagged behind [3][4]. - Notable individual stock performances included Rui Zhi Pharmaceutical (+20.06%), Yi Fang Bio (+20.00%), and Shu Tai Shen (+20.00%) leading the gainers, while Yong An Pharmaceutical (-9.99%), Jia Ying Pharmaceutical (-7.46%), and Yi Sheng Pharmaceutical (-3.62%) were among the biggest losers [3]. Summary by Sections Market Performance - On May 29, 2025, the pharmaceutical sector's performance was +2.37%, surpassing the CSI 300 index by 1.81 percentage points, with medical research outsourcing, other biological products, and in vitro diagnostics showing the highest gains [3]. Industry News - Novartis announced that its oral monotherapy, Ipratropium Bromide, received approval from the National Medical Products Administration (NMPA) in China for a new indication to treat adult patients with paroxysmal nocturnal hemoglobinuria (PNH). This drug is a complement pathway inhibitor that selectively inhibits the upstream complement pathway, addressing the shortcomings of anti-complement C5 therapies [4]. - Hai Chuang Pharmaceutical announced that its self-developed new drug, Deutero Enzalutamide soft capsules, has been approved for treating metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have progressed after receiving Abiraterone acetate and chemotherapy [4]. - Sunshine Novo announced that its subsidiary, Novo Sheng Tai, achieved expected goals in the Phase II clinical trial of STC007 injection for moderate to severe pain after abdominal surgery [4]. - Te Bao Bio announced that its product, Yipei growth hormone injection, has been approved for marketing, utilizing a long-acting growth hormone modification technology [4]. - Zejing Pharmaceutical announced that its new drug application for Jikaxitinib tablets has been approved for adult patients with intermediate or high-risk primary myelofibrosis, secondary myelofibrosis due to polycythemia vera, and essential thrombocythemia [5].